"10.1371_journal.pone.0053219","plos one","2013-01-18T00:00:00Z","Firdaus A A Mohamed Hoesein; Els Wauters; Wim Janssens; Harry J M Groen; Joanna Smolonska; Cisca Wijmenga; Dirkje S Postma; H Marike Boezen; Pim A De Jong; Marc Decramer; Jan-Willem J Lammers; Diether Lambrechts; Pieter Zanen","Division of Heart and Lungs, Department of Respiratory Medicine, University Medical Center, Utrecht, The Netherlands; Respiratory Division, University Hospital Gasthuisberg, KU Leuven, Leuven, Belgium; Vesalius Research Center, VIB, Leuven, Belgium; Vesalius Research Center, KU Leuven, Leuven, Belgium; Department of Pulmonology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Department of Radiology, University Medical Center, Utrecht, The Netherlands","Conceived and designed the experiments: PZ WJ DL. Performed the experiments: JS EW. Analyzed the data: FMH EW PZ WJ DL. Contributed reagents/materials/analysis tools: JS. Wrote the paper: FMH EW PZ WJ DL HG CW DP MB PDJ MD JL.","DS Postma received funding for research from AstraZeneca, GSK, Nycomed. Travel to ERS or ATS has been partially funded by AstraZeneca, GSK, Chiesi, Nycomed. DS Postma has been consultant to AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Nycomed, TEVA. W Janssens has been consultant and received travel grants from Boehringer Ingelheim, Astra Zeneca, Nycomed. All the other authors state that they have no conflicts of interests. The above commercial funding was not for this specific study. This study was, however, funded by Zorg Onderzoek Nederland-Medische Wetenschappen, KWF Kankerbestrijding, Stichting Centraal Fonds Reserves van Voormalig Vrijwillige Ziekenfondsverzekeringen, Siemens Germany, G. Ph. Verhagen Stichting, Rotterdam Oncologic Thoracic Steering Committee, Erasmus Trust Fund, Stichting tegen Kanker. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","01","Firdaus A A Mohamed Hoesein","FAAMH",13,TRUE,3,2,5,12,TRUE,TRUE,FALSE,0,NA,FALSE
